Machine learning research methods to predict postoperative pain and opioid use: a narrative review
- PMID: 39909542
- DOI: 10.1136/rapm-2024-105603
Machine learning research methods to predict postoperative pain and opioid use: a narrative review
Abstract
The use of machine learning to predict postoperative pain and opioid use has likely been catalyzed by the availability of complex patient-level data, computational and statistical advancements, the prevalence and impact of chronic postsurgical pain, and the persistence of the opioid crisis. The objectives of this narrative review were to identify and characterize methodological aspects of studies that have developed and/or tested machine learning algorithms to predict acute, subacute, or chronic pain or opioid use after any surgery and to propose considerations for future machine learning studies. Pairs of independent reviewers screened titles and abstracts of 280 PubMed-indexed articles and ultimately extracted data from 61 studies that met entry criteria. We observed a marked increase in the number of relevant publications over time. Studies most commonly focused on machine learning algorithms to predict chronic postsurgical pain or opioid use, using real-world data from patients undergoing orthopedic surgery. We identified variability in sample size, number and type of predictors, and how outcome variables were defined. Patient-reported predictors were highlighted as particularly informative and important to include in such machine learning algorithms, where possible. We hope that findings from this review might inform future applications of machine learning that improve the performance and clinical utility of resultant machine learning algorithms.
Keywords: Analgesics, Opioid; Methods; Pain, Postoperative; machine learning.
© American Society of Regional Anesthesia & Pain Medicine 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: While there are no conflicts of interest directly related to this work, RHD, PhD, since January 1, 2021 has received research grants and contracts from the US Food and Drug Administration and the US National Institutes of Health, and compensation for serving on advisory boards or consulting on clinical trial methods from Acadia, Akigai, Allay, AM-Pharma, Analgesic Solutions, Beckley, Biogen, Biosplice, Bsense, Cardialen, Chiesi, Clexio, Collegium, CombiGene, Confo, Contineum, Eccogene, Editas, Eli Lilly, Emmes, Endo, Epizon, Ethismos (equity), Exicure, GlaxoSmithKline, Glenmark, Gloriana, JucaBio, Kriya, Mainstay, Merck, Mind Medicine (also equity), NeuroBo, Noema, OliPass, Orion, Oxford Cannabinoid Technologies, Pfizer, Q-State, Regenacy (also equity), Rho, Sangamo, Semnur, SIMR Biotech, Sinfonia, SK Biopharmaceuticals, Sparian, SPM Therapeutics, SPRIM Health, Tiefenbacher, Validae, Vertex, Viscera, and WCG.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous